NASDAQ$KIDS
OrthoPediatrics Corp · Q3 2020 earnings
Q3 2020 earnings · · Investor relations
Briefing
OrthoPediatrics demonstrated revenue growth and improved EBITDA, achieving positive adjusted EBITDA.
OrthoPediatrics Corp. reported a 7.0% increase in total revenue for Q3 2020, reaching $22.2 million, driven by a 16.7% growth in U.S. revenue. The company also achieved positive adjusted EBITDA, reflecting strong gross margin and cost control.
- Total revenue increased by 7.0% to $22.2 million compared to Q3 2019.
- U.S. revenue grew by 16.7% compared to the same period last year.
- Adjusted EBITDA was positive during the quarter.
- Orthex execution continued strongly, with a 167% increase in first-time users year-to-date.
Headline financials
Revenue & EPS history
OrthoPediatrics · Revenue · Quarterly
$22.2M
Revenue by segment
OrthoPediatrics · $22.2M total across 3 segments · Q3 2020
- Trauma and Deformity$15M+8.2%67.4%
- Scoliosis$6.56M+1.3%29.5%
- Sports Medicine/Other$681K+55.5%3.1%
Forward guidance
The Company expects overall sales growth during the fourth quarter 2020 to be similar to the third quarter. Fourth quarter sales growth in the U.S. is expected to accelerate slightly, while the international sales decline in the fourth quarter should be similar to the third quarter.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q3 2020
-0.6%
Avg return
Earnings day
-1.0%
Avg return
5 days after
-0.4%
Avg return
30 days after
50%
17 / 34 earnings
Positive
+13.1%
Q2 2022
Best reaction
-13.0%
Q3 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +3.8% | +13.7% | +14.0% | |
| Q4 2025 | +8.3% | +3.9% | -12.8% | |
| Q3 2025 | -2.6% | -3.0% | +9.3% | |
| Q1 2025 | +4.0% | +4.6% | -4.5% | |
| Q4 2024 | +11.9% | +7.0% | -0.8% | |
| Q3 2024 | -7.8% | -16.2% | -22.3% | |
| Q2 2024 | -7.8% | -9.0% | +3.8% | |
| Q1 2024 | +5.7% | -5.3% | -1.9% | |
| Q4 2023 | +5.4% | +1.9% | +0.8% | |
| Q3 2023 | +4.2% | -5.1% | +8.9% | |
| Q2 2023 | -4.6% | -4.9% | -7.2% | |
| Q1 2023 | -7.5% | -8.0% | -14.4% | |
| Q4 2022 | +0.5% | +1.7% | -0.8% | |
| Q3 2022 | -13.0% | -12.4% | +0.8% | |
| Q2 2022 | +13.1% | +19.2% | -0.8% | |
| Q1 2022 | -10.2% | -17.7% | -8.1% | |
| Q4 2021 | -5.8% | -6.3% | -2.0% | |
| Q3 2021 | +2.0% | +0.4% | -19.4% | |
| Q2 2021 | +6.9% | +4.5% | +9.2% | |
| Q1 2021 | +10.1% | +4.4% | +4.4% | |
| Q4 2020 | -7.1% | -8.6% | +2.3% | |
| Q3 2020 | -6.5% | +6.5% | -2.1% | |
| Q2 2020 | +4.7% | +9.7% | -0.6% | |
| Q1 2020 | +2.8% | +4.8% | +10.0% | |
| Q4 2019 | +1.1% | -4.5% | -19.5% | |
| Q3 2019 | +5.7% | +8.9% | +10.6% | |
| Q2 2019 | -0.2% | -1.0% | +10.9% | |
| Q1 2019 | -9.5% | -10.3% | -8.3% | |
| Q4 2018 | -4.3% | -2.0% | -6.2% | |
| Q3 2018 | -12.5% | -16.0% | -11.4% | |
| Q2 2018 | +2.7% | +2.7% | +23.7% | |
| Q1 2018 | -1.1% | +1.9% | +32.0% | |
| Q4 2017 | -1.9% | +3.4% | -2.9% | |
| Q3 2017 | -11.3% | -2.0% | -8.5% | |
| Q1 2017 | — | — | — | |
| Q4 2016 | — | — | — | |
| Q3 2016 | — | — | — | |
| Q2 2016 | — | — | — | |
| Q1 2016 | — | — | — | |
| Q1 2015 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro